Clofarabine: Treatment of Acute Leukemia

Drugs of the Future

Volumn 29, Issue 2, 2004, Pages 112-120

  Chilman Blair, K ^a   Mealy, N E ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; CLOFARABINE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; IRINOTECAN; MELPHALAN; METHOTREXATE; PACLITAXEL; PURINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; COLORECTAL TUMOR; CROSS RESISTANCE; DIARRHEA; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERURICEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PROSTATE TUMOR; RASH; REVIEW; SOLID TUMOR; VOMITING;

EID: 1642417544     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.02.776206     Document Type: Review

References (65)

1. Reichman, U., Watanabe, K.A., Fox, J.J. A practical synthesis of 2-deoxy-2-fluoro-D-arabinofuranose derivatives. Carbohydr Res 1975, 42: 233-40.
2. Bauta, W.E., Schulmeier, B.E., Cantrell, W.R. Jr., Lovett, D., Puente, J. (Ilex Oncology, Inc.). Process for preparing purine nucleosides. US 2003114663, WO 0311877.
3. Montgomery, J.A., Fowler, A.T., Secrist, J.A. III. (Southern Research Institute). Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)-9H-purin-6-amine. CA 2400470, EP 1261350, WO 0160383.
4. Montgomery, J.A., Secrist, J.A. III. (Southern Research Institute). 2-Halo-9-(2-deoxy-2-fluoro-B-D-arabinofuranosyl) adenine nucleoside derivs. JP 1993502014, US 5034518, WO 9014352.
5. Montgomery, J.A., Shortnacy-Fowler, A.T., Clayton, S.D., Riordan, J.M., Secrist, J.A. III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem 1992, 35: 397-401.
6. Beutler, E., Carson, D.A. 2-Chlorodeoxyadenosine: Hairy cell leukemia takes a surprising turn. Blood Cells 1993, 19: 569-72.
7. Piro, L.D., Ellison, D.J., Saven, J. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994, 14: 121-5.
8. Keating, M., O'Brien, S., Plunkett, W., Robertson, L., Gandhi, V., Estey, E., Dimopoulos, M., Cabanillas, F., Kemena, A., Kantarjian, H. Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 1994, 31: 28-39.
9. Piro, L.D., Carrera, C.J., Carson, D.A., Beutler, E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 1990, 322: 1117-21.
10. Cheson, B.D. New antimetabolites in the treatment of human malignancies. Semin Oncol 1992, 19: 695-706.
11. Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J., McCredie, K.B. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74: 19-25.
12. Parker, W.B., Shaddix, S.C., Chang, C.H., White, E.L., Rose, L.M., Brockman, R.W., Shortnacy, A.T., Montgomery, J.A., Secrist, J.A. III, Bennett, L.L. Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991, 51: 2386-94.
13. Plunkett, W., Saunders, P.P. Metabolism andaction of purine nucleoside analogs. Pharmacol Ther 1991, 49: 239-68.
14. White, E.L., Shaddix, S.C., Brockman, R.W., Bennett, L.L. Jr. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 1982, 42: 2260-4.
15. Tseng, W.-C., Derse, D., Cheng, Y.-C., Brockman, R.W., Bennett, L.L. Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 1982, 21: 474-7.
16. Parker, W.B., Bapat, A.R., Shen, Y.-X., Townsend, A.J., Cheng, Y.-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase and ribonucleotide reductase. Mol Pharmacol 1988, 34: 485-91.
17. Huang, P., Chubb, S., Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 1990, 265: 16617-25.
18. Griffig, J., Koob, R., Blakley, R.L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989, 49: 6923-8.
19. Hentosh, P., Koob, R., Blakley, R.L. Incorporation of 2-halogeno-2′-deoxyadenosine 5′-triphosphate into DNA during replication by human polymerases α and β. J Biol Chem 1990, 265: 4033-40.
20. Liliemark, J., Albertioni, F., Hassan, M., Juliusson, G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 1992, 10: 1514-8.
21. Cheson, B.D., Vena, D.A., Foss, F.M., Sorensen, J.M. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994, 12: 2216-28.
22. Huang, P., Plunkett, W. Phosphorolytic cleavage of 2-fluoroadenine from 9-β-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. Biochem Pharmacol 1987, 36: 2945-50.
23. Litzow, M.R. PNAs for AML. Blood 2003, 102: 2315.
24. Kantarjian, H.M. Clofarabine - A new nucleoside analogue with significant activity in leukemia. Cancer Invest 2003, 21 (Suppl. 1): Abst 3.
25. Carson, D.A., Wasson, D.B., Esparza, L.M., Carrera, C.J., Kipps, T.J., Cottam, H.B. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′deoxyadenosine. Proc Natl Acad Sci USA 1992, 89: 2970-4.
26. Parker, W.B., Shaddix, S.C., Rose, L.M., Shewach, D.S., Hertel, L.W., Secrist, J.A. III, Montgomery, J.A., Bennett, L.L. Jr. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β -D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β -D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999, 55: 515-20.
27. Xie, C., Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995, 55: 2847-52.
28. Xie, K.C., Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β -o-arabinofuranosyl)adenine. Cancer Res 1996, 56: 3030-7.
29. Parker, W.B., Shaddix, S.C. Effect of 2-Cl-2′-F-2′ -deoxyarabinofuranosyladenine on natural nucleotide pools and its triphosphate on human DNA polymerases. Proc Am Assoc Cancer Res 1990, 31: Abst 2504.
30. Lotfi, K., Mansson, E., Spasokoukotskaja, T., Pettersson, B., Liliemark, J., Peterson, C., Eriksson, S., Albertioni, F. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999, 5: 2438-44.
31. Takahashi, T., Shimizu, M., Akinaga, S. Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF CEM. Cancer Chemother Pharmacol 2002, 50: 193-201.
32. Xie, C., Plunkett, W. Mechanism of cytotoxicity of 2-chloro-2′ -fluoro-arabinosyladenine in CEM cells. Proc Am Assoc Cancer Res 1994, 35: Abst 2308.
33. Spasokoukotskaja, T., Sasvári-Székely, M., Keszler, G., Albertioni, F., Eriksson, S., Staub, M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur J Cancer 1999, 35: 1862-7.
34. Yamauchi, T., Nowak, B.J., Keating, M.J., Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 7: 3580-9.
35. Waud, W.R., Schmid, S.M., Harrison, S.D. Jr., Secrist, J.A. III, Montgomery, J.A. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine. Proc Am Assoc Cancer Res 1992, 33: Abst 3257.
36. Waud, W.R., Schmid, S.M., Montgomery, J.A., Secrist, J.A. III. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β -o-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000, 19: 447-60.
37. Lindemalm, S., Liliemark, J., Gruber, A., Eriksson, S., Karlsson, M.O., Wang, Y., Albertioni, F. Comparison of cytotoxicity of 2-chloro-2′ -arabino-fluoro-2′-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica 2003, 88: 324-32.
38. Carrera, C.J., Cottam, H.B., Wasson, D.B., Kipps, T.J., Saven, A., Piro, L.D., Beutler, E., Carson, D.A. Stability and oral activity of 2-chloro-2′-ara-fluoro-2′-deoxyadenosine (CAFdA) in a SCID mouse model of chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 1992, 11: Abst 268.
39. Stephenson, K., Wilson, S.T., Schmid, S.M., Waud, W.R., Craig, A., Weitman, S.D. Correlation between frequency of administration and efficacy of clofarabine in the H460 human non-small cell lung tumor xenograft model Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 814.
40. Takahashi, T., Kanzawa, J., Okabe, M., Akinaga, S., Tamaoki, T. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. 10th NCI-EORTC Symp New Drugs Cancer Ther (June 16-19, Amsterdam) 1998, Abst 579.
41. Takahashi, T., Kanazawa, J., Akinaga, S., Tamaoki, T., Okabe, M. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999, 43: 233-40.
42. Cooper, T., Nowak, B., Gandhi, V. Biochemical modulation of cytarabine triphosphate by clofarabine. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 621.
43. Weitman, S.D., Wilson, S.T., Stephenson, K., Waud, W.R., Craig, A., Schmid, S.M. Antitumor effect of combination treatment with clofarabine and CPT-11 in the HT-29 human colorectal tumor xenograft model Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 820.
44. Stephenson, K., Wilson, S.T., Schmid, S.M., Waud, W.R., Craig, A., Weitman, S.D. Antitumor effect of combination treatment with clofarabine and Taxotere in the PC-3 human prostate tumor xenograft model. Proc Am Assoc Cancer Res 2003, 44(2nd ed): Abst 813.
45. Lindemalm, S., Albertioni, F., Liliemark, J. Stability and analysis of 2-chloro-2′-deoxyadenosine, 2-chloro-2′-arabino-fluoro-2′ -deoxyadenosine and 2-chloroadenine in human blood plasma. Anti-Cancer Drugs 1997, 8: 445-53.
46. Reichelova, V., Liliemark, J., Albertioni, F. Structure-activity relationships of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine and related analogues: Protein binding, lipophilicity, and retention in reversed-phase LC. J Liq Chromatogr 1995, 18: 1123-35.
47. Qian, M., Wang, X., Shanmuganathan, K., Chu, C.K., Gallo, J.M. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol 1994, 33: 484-8.
48. Gandhi, V., Robertson, L.E., Plunkett, W. 2-Chloro-2′ -fluoro-arabinosyladenine: Pharmacokinetics and action in chronic lymphocytic leukemia cells. Proc Am Assoc Cancer Res 1993, 34: Abst 2471.
49. Albertioni, F., Hassan, M., Silberring, J., Liliemark, J. Kinetics and metabolism of 2-chloro-2′-deoxyadenosine and 2-chloro-2′ -arabino-fluoro-2′-deoxyadenosine in the isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 1995, 20: 225-32.
50. Cunningham, C.C., Nemunaitis, J., Senzer, N., Vukelja, S., Weiss, J., Ferrier, A., Craig, A.R. A phase I dose-finding and safety study of clofarabine in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 605.
51. Gandhi, V., Kantarjian, H.M., Faderl, S. et al. Cellular pharmacokinetics and pharmacodynamics of clofarabine (2-chloro-2′ -fluoro-arabinosyladenine) in acute leukemia blasts during a phase I clinical trial. Proc Am Assoc Cancer Res 2002, Suppl.: Abst LB-124.
52. Kantarjian, H.M., Gandhi, V., Kozuch, P. et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21: 1167-73.
53. Kantarjian, H.M., Gandhi, V.V., O'Brien, S. et al. Phase I and pharmacology study of clofarabine (2-Cl-2′ -F-deoxy-9-D-arabino-furanosyladenine) in solid and hematologic cancers. Blood 2001, 98(11, Part 2): Abst 4568.
54. Kozuch, P., Ibrahim, N., Khuri, F. et al. Phase I clinical and pharmacological study of clofarabine. Blood 1999, 94(10, Suppl. 1, Part 1): 127a.
55. Kantarjian, H., Gandhi, V., Cortes, J. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102: 2379-86.
56. Cortes, J.E., Gandhi, V., Plunkett, W. et al. Clofarabine [2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine] is active for patients with refractory or relapsed acute leukemias, myelodysplastic syndromes (MDS) and chronic myeloid leukemia in blast phase (CML-BP). Blood 2002, 100(11, Part 1): Abst 739.
57. Foran, J.M., Faderl, S., Wetzler, M., Dipersio, J., Rizzieri, D., Kantarjian, H., Craig, A., Weiss, J., Douer, D. A phase II, open-label study of clofarabine in adult patients with refractory Dr relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003, 22: Abst 2360.
58. Foran, J., Wetzler, M., Kantarjian, H.M., Faderl, S., Abramson, N., Rizzieri, D.A., Craig, A., Weiss, J., Douer, D. A phase II, open-label study of Clofarex™ in adult patients with refractory or relapsed acute myelogenous leukemia. Blood 2002, 100(11, Part 2): Abst 4613.
59. Faderl, S., Gandhi, V., Garcia-Manero, G. et al. Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS). Blood 2003, 102(11, Part 1): Abst 2271.
60. Jeha, S., Gandhi, V., Chan, K.W. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103: 784-9.
61. Jeha, S., Gandhi, V., Chan, K.W., McDonald, L., Ramirez, I., Rytting, M.E., Madden, R., Keating, M.J., Plunkett, W. Jr., Kantarjian, H. Phase I study of clofarabine (Clofarex™) in pediatric leukemia. Blood 2002, 100(11, Part 1): Abst 315.
62. Jeha, S.C., McDonald, L.R., Chan, K., Tubergen, D., Ramirez, I., Kantarjian, H. Clofarabine (Clofarex) is an active agent in pediatric leukemias. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1585.
63. Jeha, S.C., Steinherz, P., Razzouk, B., Kadota, R., Rheingold, S., Gaynon, P., Bomgaars, L., Craig, A., Bishop, R., Arceci, R. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia. Proc Am Soc Clin Oncol 2003, 22: Abst 3251.
64. Jeha, S., Steinherz, P., Gaynon, P. et al. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous leukemia. Blood 2003, 102(11, Part 1): Abst 2278.
65. Jeha, S., Gaynon, P., Steinherz, P. et al. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2003, 102(11, Part 1): Abstr 3277.